Novo Nordisk spies great hemophilia opportunities with partner Genmab
![Martin Holst Lange, executive vice president of development at Novo Nordisk | Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13700543.ece/ALTERNATES/schema-16_9/doc7jjxkptuiupu07au3v2.jpg)
Novo Nordisk’s lucrative biopharma arm has stopped hemorrhaging, but growth is still a way away following years of this being the status quo. The hemophilia treatment Mim8 could speed up this process.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Biopharma sales slightly lower than expected at Novo Nordisk
For subscribers